KRYSHealthcare · BiotechnologyThe 10 Wall Street analysts covering Krystal Biotech, Inc. hold a median 12-month price target of $387 — +23.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 73 of 100 as at 1 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Krystal Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (94): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (30): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.
The rank is the raw material. Whether the rules would actually own Krystal Biotech, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on KRYS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +23.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 July 2026 | B of A Securities | Maintains | Buy | $364 → $396 |
| 18 June 2026 | TD Cowen | Maintains | Buy | — |
| 16 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 June 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 May 2026 | Citigroup | Maintains | Buy | — |
| 5 May 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 4 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2026 | Wolfe Research | Initiates | Peer Perform | — |
| 25 Feb 2026 | Guggenheim | Maintains | Buy | — |
| 18 Feb 2026 | Chardan Capital | Maintains | Buy | — |
| 18 Feb 2026 | Citigroup | Maintains | Buy | — |
| 17 Feb 2026 | Jefferies | Maintains | Buy | — |
| 2 Feb 2026 | Goldman Sachs | Maintains | Buy | — |
| 22 Jan 2026 | B of A Securities | Maintains | Buy | — |
| 12 Jan 2026 | Citigroup | Maintains | Buy | — |
| 9 Jan 2026 | Citigroup | Maintains | Buy | — |
| 9 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Jan 2026 | TD Cowen | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 17% of US stocks
Cheaper than 8% of US stocks
Cheaper than 13% of US stocks
Cheaper than 5% of US stocks
Higher than 81% of US stocks
Higher than 79% of US stocks
Higher than 98% of US stocks
Higher than 95% of US stocks
Higher than 96% of US stocks
Higher than 82% of US stocks
Higher than 91% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KRYS appears on the weeks it earns a place.
Krystal Biotech, Inc. published its Q2 2026 earnings call transcript. The transcript covers the company's quarterly financial and business discussion.
Why it matters — A KRYS watcher would review the transcript for management's commentary on the company's quarterly performance.
Investors Business Daily reports that stocks including Eli Lilly, Twilio, and Hinge Health face a key test as they move ahead of earnings reports, advising investors to pay attention to important chart lines. Krystal Biotech (KRYS) is not mentioned in this item.
Why it matters — KRYS is not referenced in this item, so it offers no direct news about the company for Krystal Biotech watchers.
Krystal Biotech reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period. The increase came as the company expanded treatment access for patients with dystrophic epidermolysis bullosa (DEB) in the United States and overseas.
Why it matters — The 24% year-over-year revenue growth and expanding DEB treatment access indicate continued commercial traction for Krystal Biotech’s VYJUVEK.
Krystal Biotech reported Q2 earnings of $1.79 per share, surpassing the Zacks Consensus Estimate of $1.70 per share and up from $1.29 per share in the same quarter last year.
Why it matters — The earnings beat and year-over-year growth signal continued financial outperformance, which KRYS watchers may view as a sign of strong operational execution.
Krystal Biotech reported second-quarter 2026 financial results, including $119.2 million in global VYJUVEK revenue for the quarter and $965.9 million since launch, ending with $1.1 billion in cash and investments. The company also noted it remains on track for VYJUVEK launches in Spain and Italy and expects multiple clinical data readouts in the second half of 2026.
Why it matters — KRYS watchers would follow this update because VYJUVEK revenue trends, upcoming European launches, and near-term pipeline catalysts could signal the company's commercial and clinical momentum.
The 10 Wall Street analysts covering Krystal Biotech, Inc. have a median 12-month price target of $387, with estimates ranging from $284 to $474. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Krystal Biotech, Inc., 9 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Krystal Biotech, Inc. 73 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Krystal Biotech, Inc. ranks 73 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (94 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +23.7% from the last close, and Ticker Nerd's factor model ranks Krystal Biotech, Inc. 73 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Krystal Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KRYS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $284 to $474 over the next 12 months.
Krystal Biotech, Inc. returned +99.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Krystal Biotech Inc. is a commercial-stage biotechnology company focused on developing and commercializing genetic medicines for severe, life-threatening, and rare diseases with high unmet medical needs.
The most recent item we track (Seeking Alpha, 3 Aug 2026): "Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call Transcript". Krystal Biotech, Inc. published its Q2 2026 earnings call transcript. The transcript covers the company's quarterly financial and business discussion.
Krystal Biotech Inc. is a commercial-stage biotechnology company focused on developing and commercializing genetic medicines for severe, life-threatening, and rare diseases with high unmet medical needs. The company specializes in redosable gene therapies built on a proprietary herpes simplex virus type 1 (HSV-1) vector platform, enabling targeted delivery of therapeutic genes to skin and other tissues. Krystal Biotech’s core area of impact is specialty dermatology, where it offers Vyjuvek, a prescription gene therapy for dystrophic epidermolysis bullosa, a rare inherited skin disorder characterized by extreme fragility and chronic wounds. Beyond dermatology, the company is advancing a pipeline that extends its platform into oncology and respiratory indications, aiming to address complex solid tumors and genetic lung diseases through localized gene delivery. Krystal Biotech operates as a fully integrated enterprise, with in-house CGMP manufacturing facilities to support discovery, clinical development, and commercial supply of its therapies. Founded in 2016 and headquartered in Pittsburgh, Pennsylvania, Krystal Biotech plays a distinct role in the biotechnology market as a leader in redosable gene therapy for rare conditions.
CEO Mr. Krish S. Krishnan M.B.A., M.S. · 295 employees · United States · https://www.krystalbio.com